MAPT and early-onset autosomal dominant Alzheimer disease: In vivo, W1302 also showed neuroprotective effects in the treatment of Alzheimer’s disease (AD) by activating NO- and GABA-dependent signaling in MK-801 [12] or scopolamine [13] impaired mice, stimulating an NO/sGC/cGMP signal transduction cascade in rats after forebrain cholinergic depletion [14], reducing neurotoxic forms of Aβ or tau protein, restoring neuronal plasticity, antioxidant activity, and anti-neuroinflammation, and improving long-term potentiation (LTP) via CREB/BNDF signaling in a novel sporadic model of Alzheimer’s disease and multiple familial mouse models [15].